Insider Trading Alert - OLED, MASI And BIOS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 21, 2015, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $233.20 to $1,180,446,250.00.

Highlighted Stocks Traded by Insiders:

Universal Display (OLED) - FREE Research Report

Becker Leonard, who is Director at Universal Display, sold 8,750 shares at $51.24 on May 21, 2015. Following this transaction, the Director owned 27,500 shares meaning that the stake was reduced by 24.14% with the 8,750-share transaction.

The shares most recently traded at $53.50, up $2.26, or 4.22% since the insider transaction. Historical insider transactions for Universal Display go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 47,708
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 938,659
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 938,659

The average volume for Universal Display has been 740,100 shares per day over the past 30 days. Universal Display has a market cap of $2.4 billion and is part of the technology sector and electronics industry. Shares are up 89.37% year-to-date as of the close of trading on Thursday.

Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel displays and solid-state lighting applications. The company has a P/E ratio of 62.6. Currently, there are 3 analysts who rate Universal Display a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OLED - FREE

TheStreet Quant Ratings rates Universal Display as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Universal Display Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Masimo (MASI) - FREE Research Report

Fishel Rick, who is Pres, WW OEM Bus & Blood Mgmt at Masimo, sold 15,000 shares at $32.85 on May 21, 2015. Following this transaction, the Pres, WW OEM Bus & Blood Mgmt owned 57,022 shares meaning that the stake was reduced by 20.83% with the 15,000-share transaction.

The shares most recently traded at $35.69, up $2.84, or 7.96% since the insider transaction. Historical insider transactions for Masimo go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares sold: 8,000

The average volume for Masimo has been 373,800 shares per day over the past 30 days. Masimo has a market cap of $1.9 billion and is part of the health care sector and health services industry. Shares are up 34.85% year-to-date as of the close of trading on Thursday.

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company has a P/E ratio of 27.7. Currently, there are 2 analysts who rate Masimo a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MASI - FREE

TheStreet Quant Ratings rates Masimo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Masimo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioScrip (BIOS) - FREE Research Report

Golding David W, who is Director at BioScrip, bought 10,000 shares at $4.02 on May 21, 2015. Following this transaction, the Director owned 10,000 shares meaning that the stake was boosted by 100% with the 10,000-share transaction.

The shares most recently traded at $3.78, down $0.24, or 6.24% since the insider transaction. Historical insider transactions for BioScrip go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 10,000
  • 24-Week # shares bought: 10,000

The average volume for BioScrip has been 1.7 million shares per day over the past 30 days. BioScrip has a market cap of $256.8 million and is part of the health care sector and health services industry. Shares are down 46.21% year-to-date as of the close of trading on Thursday.

BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in two segments, Infusion Services and PBM Services. Currently, there are 6 analysts who rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIOS - FREE

TheStreet Quant Ratings rates BioScrip as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full BioScrip Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?